Cosentyx (secukinumab) is a biologic medication used to treat various inflammatory diseases such as psoriasis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis [1], [2]. The typical dosing regimen for Cosentyx involves subcutaneous injections [3].

According to the manufacturer's prescribing information, the recommended dosing frequency for Cosentyx varies depending on the specific condition being treated.

For the treatment of moderate-to-severe plaque psoriasis, Cosentyx is administered via a subcutaneous injection every 2 weeks for 5 doses, followed by a maintenance dose every 4 weeks [1].

For the treatment of psoriatic arthritis, Cosentyx is administered via a subcutaneous injection every 2 weeks for 5 doses, followed by a maintenance dose every 4 weeks [2].

For the treatment of ankylosing spondylitis, Cosentyx is administered via a subcutaneous injection every 4 weeks.

Cosentyx is available in a pre-filled syringe or a pre-filled pen injector, with each syringe or pen containing a single dose [4].

Referring to DrugPatentWatch.com [5], we see that the Cosentyx dosing regimen has been approved and monitored by regulatory agencies, including the US FDA.

In typical use, Cosentyx injections are administered by patients themselves or by a healthcare professional. It's essential for patients to follow the prescribed dosing regimen and seek medical attention if they have any questions or concerns about their medication.

Sources:

[1] https://www.cosentyxhcp.com/sites/g/files/gyqnrq221/files/docs/PIcsec.pdf
[2] https://www.cosentyxhcp.com/sites/g/files/gyqnrq221/files/docs/picsec_psoriatic-arthritis.pdf
[3] https://www.cosentyxhcp.com/sites/g/files/gyqnrq221/files/docs/secukinumab.pdf
[4] https://www.cosentyxhcp.com/
[5] https://www.drugpatentwatch.com/Drugs/Cosentyx